Spike Protein Detox & Mitochondrial Recovery: The Complete 2026 Guide to FLCCC I-Recover, McCullough Base Spike Detox, and Phased Bioenergetic Resuscitation
Quick Answer: Persistent SARS-CoV-2 spike protein — from infection, vaccination, or both — is linked to Long COVID and post-vaccine syndrome through immune dysregulation, microclotting, and mitochondrial bioenergetic failure. The two leading clinical frameworks are Dr. Peter McCullough's Base Spike Detox (nattokinase + bromelain + curcumin) and the FLCCC I-Recover Post-Vaccine Protocol (a graduated, symptom-guided, multi-tier regimen). Because stimulating metabolism or degrading spike too quickly can trigger Herxheimer-like flares, this guide sequences both frameworks through a 4-phase bioenergetic resuscitation protocol — Neutralize → Recharge → Clean & Degrade → Rebuild — and adds symptom-specific adjuncts for neurological, cardiac, thrombotic, and MCAS presentations. Baseline spike antibody testing and physician oversight are recommended throughout, particularly for anyone on anticoagulants or SSRIs/SNRIs.
Keywords: spike protein detox, Long COVID, post-vaccine syndrome, FLCCC I-Recover, McCullough Base Spike Detox, mitochondrial bioenergetics, mtROS, nattokinase, bromelain, curcumin, NAD+, mitophagy, ivermectin
Table of Contents
- Background & Pathophysiology
- Mitochondrial Mechanisms of Injury
- Spike Antibody Testing & Baseline
- Framework 1: McCullough Base Spike Detox
- Framework 2: FLCCC I-Recover Hierarchy
- The 4-Phase Bioenergetic Resuscitation Protocol
- Symptom-Specific Adjuncts
- Unified Framework Comparison
- Clinical Safety & Drug Interactions
- Using AI to Personalize Your Protocol
- Where to Source the Protocols
- Frequently Asked Questions
- References
Abstract
Post-acute sequelae of SARS-CoV-2 infection and COVID-19 vaccination (PASC/PVS) are complex, multi-systemic disorders driven by immune dysregulation, microvascular inflammation, persistent spike protein, and mitochondrial impairment. This white paper unifies three complementary clinical resources into a single reference: (1) Dr. Peter McCullough's Base Spike Detox TIER 4 — the first triple-compound, OTC spike-clearance regimen published in the peer-reviewed US literature; (2) the FLCCC I-Recover Post-Vaccine Protocol TIER 2 — a graduated, symptom-individualized framework from the Independent Medical Alliance; and (3) a 4-phase bioenergetic resuscitation protocol that sequences proteolytic spike degradation with targeted mitochondrial repair (mtROS scavenging, NAD+ restoration, mitophagy activation, and photobiomodulation) to minimize Herxheimer-like flares and post-exertional crashes. Baseline and follow-up spike protein antibody testing, symptom-specific adjuncts, and an AI-assisted personalization framework (Claude, ChatGPT, Gemini, Perplexity) round out the guide. Controlled clinical trials remain essential to validate dose titration and long-term efficacy across all three frameworks.
1. Background & Pathophysiology
Although no single official definition exists for post-COVID-vaccine syndrome, a temporal correlation between COVID-19 vaccination and the onset or worsening of otherwise-unexplained clinical manifestations provides sufficient grounds for clinical diagnosis under the frameworks developed by the Independent Medical Alliance (IMA, formerly FLCCC) TIER 4. The same pathophysiological cascade is implicated in Long COVID arising from natural infection, where symptoms persisting months to years after acute illness are characterized by profound fatigue, cognitive impairment ("brain fog"), autonomic instability, dyspnea, and exercise intolerance TIER 2.
The scientific community has moved past the initial phase of merely documenting symptoms. Research is now focused on actionable biological mechanisms, including:
- Antigen Persistence: Evidence showing persistent viral reservoirs or spike protein fragments circulating in tissues long after initial exposure.
- Mitochondrial & Bioenergetic Failure: Studies demonstrating direct impairment of mitochondrial respiratory chain function, leading to cellular energy deficits and post-exertional malaise (PEM).
- Microvascular Thrombosis: The role of fibrinoid microclots and endothelial damage in impairing tissue oxygenation.
- Immune Dysregulation: Autoantibody production, latent virus reactivation (like EBV), and persistent low-grade neuroinflammation.
Long COVID continues to exert a measurable drag on global labor markets and healthcare systems. Prolonged disability, reduced working hours, and chronic care management place a sustained burden on individuals, employers, and health insurance infrastructure.
Dr. Peter McCullough has described the spike protein as an engineered, synthetic molecule of roughly 1,200 amino acids that resists degradation by the body's normal proteases. He has stated the protein was modified in laboratory settings — notably at the Wuhan Institute of Virology — to bind tightly to the ACE2 receptor, which is expressed throughout the lungs, heart, endothelium, kidneys, and brain. Because ACE2 also regulates angiotensin metabolism, individuals with fewer ACE2 sites, including older adults, catabolize spike less efficiently, which McCullough associates with worse outcomes TIER 4. These are McCullough's characterizations rather than an independently verified scientific consensus, and readers should weigh them against the peer-reviewed evidence tiers cited throughout this article.
Emerging pathophysiological models identify the persistent SARS-CoV-2 spike glycoprotein (S1 subunit) as a central driver in both post-infection and post-vaccination syndromes. Unlike typical transient viral antigens, full-length or truncated spike proteins have been detected in circulating monocytes, plasma, extracellular vesicles, and organ tissue biopsies for up to 6 to 15 months following exposure. Over 300 published papers have documented spike protein deposits in cardiac, cerebrovascular, and vascular tissue, associated with post-vaccine myocarditis, stroke, clotting disorders, and autoimmune cross-reactivity TIER 2.
2. Mitochondrial Mechanisms of Injury
Core mechanism: circulating and tissue-bound spike protein directly disrupts cellular energy machinery. By impairing mitochondrial electron transport chain (ETC) activity and destabilizing mitochondrial membrane potential (ΔΨm), spike protein converts energy-producing organelles into sources of cytotoxic mitochondrial reactive oxygen species (mtROS) TIER 3.
2.1 Mitochondrial Membrane Potential & mtROS Generation
Spike protein interactions with host-cell receptors, including ACE2 and CD147, trigger intracellular signaling cascades that alter mitochondrial calcium homeostasis. The resulting calcium overload opens the mitochondrial permeability transition pore (mPTP), depolarizing the membrane and uncoupling oxidative phosphorylation. Electron leakage across Complexes I and III then increases, driving mtROS overproduction and lipid peroxidation TIER 3.
2.2 PBMC Respiration & Cardiovascular Impairment
Clinical evaluation of peripheral blood mononuclear cells (PBMCs) in Long COVID cohorts reveals significantly reduced basal and maximal oxygen consumption rates (OCR), and this impaired respiration correlates with mortality and Long COVID severity TIER 2. In cardiac tissue, spike protein directly affects pericytes and cardiomyocytes, suppressing ATP yield and driving microvascular inflammation — manifesting clinically as severe muscle fatigability, post-exertional malaise (PEM), and autonomic dysregulation.
2.3 Antigen Persistence & Microvascular Thrombosis
Spike protein also induces resistant amyloid-like microclots by interacting directly with fibrinogen, causing haemagglutination effects that physically obstruct capillary networks TIER 3. This worsens tissue hypoxia and creates a feed-forward loop of localized ischemia, mitochondrial decay, and persistent immune activation. Conventional approaches that target single downstream symptoms frequently fail because the underlying mitochondrial degradation and antigenic trigger remain unaddressed — which is why this guide pairs proteolytic clearance with structured bioenergetic repair (Section 6).
| Mechanism | Clinical Manifestation | Evidence |
|---|---|---|
| Persistent spike protein / immune dysregulation | Fatigue, brain fog, autoimmunity | TIER 2 |
| Spike-induced haemagglutination & microclots | Hypoxia, DVT, pulmonary embolism, stroke | TIER 3 |
| Mast cell activation syndrome (MCAS) | Allergic reactions, histamine symptoms, GI distress | TIER 4 |
| Herpesvirus reactivation (EBV, HSV, VZV) | Shingles, cold sores, EBV reactivation syndrome | TIER 2 |
| Mitochondrial dysfunction / oxidative stress | Fatigue, exercise intolerance, PEM | TIER 3 |
| Vaccine-induced myocarditis / pericarditis | Chest pain, cardiac arrhythmia, reduced EF | TIER 1 |
3. Spike Antibody Testing & Baseline
Before initiating any protocol element, Dr. McCullough recommends obtaining a quantitative spike protein antibody test to establish a baseline and track progress. The key test is the SARS-CoV-2 Spike Protein Antibody (Semi-Quantitative), available through Labcorp in most US states (order at labcorp.com); Healthlabs.com and Attomarker's COVID Antibody Spectrum Test are alternatives. Antibodies are an indirect reflection of spike protein and do not change rapidly — do not retest sooner than 6–12 months after starting a protocol.
| Spike Ab Level (U/ml) | Clinical Interpretation | Recommended Action |
|---|---|---|
| < 1,000 | Very low — negligible risk | Maintenance / reassurance; retest in 12 months if symptomatic |
| 1,000 – 5,000 | Symptoms may be spike-related | Initiate Base Spike Detox; add I-Recover first-line agents |
| 5,000 – 10,000 | Likely circulating spike — elevated risk | Full Base Spike Detox + physician consultation; consider ivermectin |
| > 10,000 | Very high risk — cardiac, clotting, neuro, autoimmune concern | Urgent physician review; full I-Recover protocol; anticoagulation assessment |
4. Framework 1: McCullough Base Spike Detox
Published in Cureus (November 2023), the Base Spike Detox is the first spike-protein clearance protocol to appear in the peer-reviewed US medical literature. It uses three OTC nutraceuticals with complementary mechanisms to degrade and clear spike protein fragments via the reticuloendothelial system.
| Compound | Dose & Timing | Mechanism | Evidence |
|---|---|---|---|
| Nattokinase | 2,000 FU (100 mg) twice daily, empty stomach | Direct spike protein degradation; fibrinolytic — degrades fibrin microclots; D-dimer elevation confirms fibrinolytic activity | TIER 3 |
| Bromelain | 500 mg once daily, empty stomach | Proteolytic clearance of spike fragments; prolongs prothrombin time; anti-inflammatory via cytokine inhibition | TIER 4 |
| Nano / Liposomal Curcumin | 500 mg twice daily, with food | NF-κB inhibition; antioxidant; supports autophagy; inhibits mast cell degranulation; antiplatelet/anti-fibrin effects | TIER 2 (general anti-inflammatory RCTs); TIER 4 (spike-specific use) |
Duration: minimum 3 months; typically 6–12 months; continue indefinitely if well tolerated and spike Ab remains elevated. Blood-thinner caution: nattokinase and bromelain meaningfully increase anticoagulant effect — physician supervision is mandatory alongside warfarin, apixaban, rivaroxaban, or dabigatran. Soy allergy: avoid nattokinase (fermented soybean origin). Pregnancy / children: not recommended without direct physician guidance.
"March 2024 Spike Antibody 1:25,000. Using the McCullough protocol now six months, my Spike antibody down to 1:740 in September 2024." — Dr. Robert W. Enzenauer, MD, MPH, physician self-report (September 2024) TIER 4
5. Framework 2: FLCCC I-Recover Hierarchy
The FLCCC I-Recover protocol, now maintained by the Independent Medical Alliance, provides a graduated, symptom-guided framework built on two complementary strategies: (A) promoting autophagy so cells can clear spike protein fragments, and (B) limiting spike toxicity during the clearance process. Treatment must be individualized — an intervention life-saving for one patient may be ineffective for another.
First-Line Therapies (in order of importance)
| Intervention | Dose / Notes | Evidence |
|---|---|---|
| Intermittent fasting / time-restricted eating | 16:8 minimum; periodic 24–48 h fasts | TIER 2 |
| Ivermectin (Rx) | 0.2–0.3 mg/kg daily (responders); up to 0.5 mg/kg/day in severe cases; take with food | TIER 2 |
| Moderate physical activity | Light walking, yoga, tai chi; avoid over-exertion (PEM risk) | TIER 4 |
| Nattokinase | 100–200 mg (2,000–4,000 FU) twice daily, empty stomach | TIER 3 |
| L-Arginine + Vitamin C | L-Arginine 1.5–2 g BID; liposomal Vitamin C 1,000 mg 2–3×/day | TIER 2 |
| Low-Dose Naltrexone (LDN, Rx) | 1–4.5 mg daily | TIER 4 |
| MCAS treatment | H1 blockers (cetirizine 5–10 mg, loratadine 10 mg); H2 blockers (famotidine 20 mg BID) | TIER 4 |
| Sunlight & photobiomodulation | Daily natural light; 660–850 nm red/NIR device | TIER 4 |
| Melatonin | 2–6 mg slow/extended release at bedtime | TIER 4 |
| Bromelain + NAC | Bromelain 500 mg empty stomach; NAC 600–1,500 mg/day | TIER 4 |
| Nigella sativa (black seed oil) | 200–500 mg BID — caution: serotonin syndrome risk with opioids | TIER 2 |
| Resveratrol / Quercetin | Resveratrol 500 mg/day; Quercetin 500 mg BID (zinc ionophore) | TIER 3 |
| Probiotics / prebiotics | Multi-strain probiotic daily; high-fibre foods | TIER 1 |
| Metformin (Rx) | 500–1,000 mg/day | TIER 1 (41% reduced Long COVID incidence, COVID-OUT RCT) |
Second-Line Therapies
| Intervention | Dose / Notes | Evidence |
|---|---|---|
| Vitamin D3 + K2 | D3 4,000–5,000 IU/day; K2 100 mcg/day | TIER 2 |
| NAC | 600–1,500 mg/day | TIER 3 |
| Omega-3 (EPA/DHA) | 1–4 g/day combined | TIER 2 |
| Magnesium | 200–400 mg/day (glycinate or malate) | TIER 2 |
| Sildenafil (Rx) | With or without L-Arginine / L-Citrulline | TIER 2 |
| Spermidine | 1–5 mg/day | TIER 3 |
| IV Vitamin C | 25 g weekly IV + oral 1 g 2–3×/day | TIER 4 |
Third-Line Therapies (specialist referral generally required)
| Intervention | Notes |
|---|---|
| Hyperbaric Oxygen (HBOT) | Neurological regeneration; microclot resolution; 40-session protocols show cognitive improvement TIER 1 |
| Mitochondrial optimizer stacks | PQQ + CoQ10 + NADH + glycophospholipids |
| Low-dose corticosteroid | Only for refractory, established autoimmune presentations; may worsen immune dysregulation in most cases |
⚠ Anaesthesia / Surgery Warning. Patients should notify their anaesthesia team if using methylene blue, curcumin, nigella sativa, or SSRIs, as these can raise serotonin syndrome risk with opioid administration.
6. The 4-Phase Bioenergetic Resuscitation Protocol
The two frameworks above are powerful but not sequenced by default — stimulating metabolism before mitochondria are stabilized can escalate mtROS, and degrading spike protein too aggressively can trigger Herxheimer-like flares. This 4-phase protocol integrates Base Spike Detox and I-Recover components into a staged sequence — Neutralize → Recharge → Clean & Degrade → Rebuild — designed to restore cellular energy dynamics while minimizing adverse reactions and post-exertional crashes.
Neutralization — mtROS Scavenging & Anti-Inflammatory Base
Objective: quench free-radical generation and suppress inflammasome activation before metabolic stimulation.
- MitoQ (10–20 mg/day): mitochondria-targeted antioxidant that concentrates in the inner mitochondrial membrane to neutralize matrix ROS. TIER 3
- Curcumin (500 mg twice daily): suppresses NF-κB and NLRP3 inflammasomes; reduces cardiac pericyte mtROS. TIER 2
- Ubiquinol / CoQ10 (100–300 mg/day): protects membrane lipids against peroxidation; supports ETC electron transit. TIER 3
- NAC (600–1,200 mg/day) + Alpha-Lipoic Acid (300–600 mg/day): substrates for endogenous glutathione synthesis. TIER 3
Bioenergetic Recharging — NAD+ & Metabolic Bypass
Objective: rebuild depleted NAD+ pools and restore ATP synthesis via electron-bypass mechanisms.
- NAD+ precursors (NMN or NR, 300–600 mg/day): replenish intracellular NAD+, activating SIRT3 to stimulate mitochondrial bioenergetic enzymes. TIER 3; Nicotinamide Riboside specifically showed cognitive-recovery benefit in a 2025 RCT TIER 1
- Low-dose Methylene Blue (0.5–1 mg/kg/day): alternative electron cycler, accepting electrons from NADH and transferring them to Cytochrome c, bypassing impaired Complexes I and III. TIER 3
- Metabolic cofactors: B-complex vitamins (B1, B2, B3) and magnesium glycinate (200–400 mg) to support TCA cycle enzyme kinetics.
Proteolytic Cleavage & Mitophagy Activation
Objective: enzymatically degrade circulating spike protein, disrupt microclots, and clear damaged organelles via mitophagy. This phase is where the McCullough Base Spike Detox (Section 4) is introduced.
- Nattokinase (2,000 FU / 100 mg twice daily): cleaves full-length spike glycoprotein and dissolves microclots. TIER 3
- Bromelain (500 mg daily): synergistic spike cleavage and microvascular anti-inflammatory action. TIER 4
- Spermidine (2–5 mg/day) or Quercetin (500 mg/day): triggers AMPK-mediated mitophagy — selective autophagic clearance of dysfunctional, ROS-leaking mitochondria. TIER 3
- Pulsed fasting (12–14 hours overnight): enhances basal cellular autophagy — apply only once baseline energy is stable.
Biogenesis & Functional Expansion
Objective: stimulate new mitochondrial biogenesis via PGC-1α and safely expand aerobic capacity.
- Photobiomodulation (red / near-infrared light): 660 nm / 850 nm wavelengths excite Cytochrome c Oxidase (Complex IV), stimulating ATP generation and nitric oxide release. TIER 4
- Paced Zone 1 activity: sub-anaerobic, heart-rate-capped activity to induce PGC-1α-driven mitochondrial biogenesis without crossing the anaerobic threshold or triggering PEM. Informed by PBMC respiration data. TIER 2
| Phase | Therapeutic Agents | Mechanism | Clinical Objective |
|---|---|---|---|
| 1. Neutralize | MitoQ, Curcumin, Ubiquinol, NAC, ALA | Scavenges mtROS; inhibits NLRP3 inflammasome | Quench active inflammation & cellular stress |
| 2. Recharge | NMN/NR, Methylene Blue, Mg, B-complex | Restores NAD+; activates SIRT3; bypasses ETC Complexes I/III | Restore baseline cellular ATP production |
| 3. Clean & Degrade | Nattokinase, Bromelain, Spermidine, Quercetin | Proteolytic spike cleavage; microclot lysis; mitophagy activation | Remove antigenic load & recycle toxic organelles |
| 4. Rebuild | Photobiomodulation, Zone 1 pacing | Excites Cytochrome c Oxidase; activates PGC-1α biogenesis | Expand aerobic pool without triggering PEM |
This sequencing addresses two common failure points in Long COVID management: stimulating cellular metabolism while mitochondria remain damaged (which escalates mtROS), and attempting proteolytic spike degradation without adequate anti-inflammatory buffering first.
7. Symptom-Specific Adjuncts
7.1 Neurological Symptoms, Brain Fog & Fatigue
LDN plays a pivotal role. Consider fluvoxamine (starting 12.5 mg/day, titrate slowly; fluoxetine 20 mg/day as an alternative), nigella sativa (200–500 mg BID), luteolin (20–100 mg/day), valproic acid, and pentoxifylline. Note: ivermectin does not readily cross the blood-brain barrier in humans due to P-glycoprotein exclusion. Nicotinamide Riboside showed benefit for NAD+ restoration and cognitive recovery in a 2025 RCT TIER 1.
7.2 Mast Cell Activation Syndrome (MCAS)
H1 + H2 dual blockade (cetirizine/loratadine + famotidine); curcumin 500 mg/day; luteolin 20–100 mg/day; vitamin C 1,000 mg BID; low-histamine diet; montelukast 10 mg/day with caution (possible depressive side effect).
7.3 Elevated D-Dimer / Thrombosis
NOAC or coumadin ≥ 3 months then reassess; aspirin 81 mg/day (unless high bleeding risk); lumbrokinase; curcumin 500 mg BID (anticoagulant, antiplatelet, fibrinolytic properties). For select patients: triple anticoagulation, maximum 1 month, high bleeding risk — counsel carefully. Pentoxifylline + sildenafil for marked microvascular disease.
7.4 Vaccine-Induced Myocarditis / Pericarditis
ACE inhibitor/ARB + carvedilol; colchicine 0.6 mg/day (up to 0.6 mg BID) for pericarditis; CoQ10 200–400 mg/day; omega-3 EPA/DHA 1–4 g/day. A December 2024 case report described nattokinase, bromelain, curcumin, colchicine, and rapamycin resolving vaccine-induced myopericarditis. Urgent cardiology referral / ER for persistent chest pain.
7.5 Herpesvirus Reactivation (EBV, HSV, VZV / Shingles)
L-Lysine 1,000 mg BID; valacyclovir 500–1,000 mg BID for 7–10 days; spironolactone 50–100 mg/day (antiviral vs. EBV); zinc 40 mg/day; quercetin 500 mg BID. Avoid arginine-rich foods (nuts, seeds, chocolate, whole grains) during outbreaks.
7.6 Tinnitus & Hearing Loss
ENT / audiologist evaluation to exclude underlying pathology, alongside the general protocol above. Tinnitus remains one of the most frequent and disabling complications of post-vaccine syndrome.
7.7 Bell's Palsy / Facial Paresthesia
LDN 1 mg/day, titrating to 4.5 mg/day over 2–3 months. Low-dose prednisone 10–15 mg/day for 3 weeks, then taper. Reduce activity and stress.
8. Unified Framework Comparison
| Feature | McCullough Base Spike Detox | FLCCC I-Recover | 4-Phase Bioenergetic Protocol |
|---|---|---|---|
| Core compounds | Nattokinase + Bromelain + Curcumin (OTC) | Multi-tier; 15+ first-line agents incl. Rx drugs | Sequences both frameworks + MitoQ, NAD+ precursors, photobiomodulation |
| Primary target | Spike protein degradation & fibrinolysis | Broad immune restoration & autophagy | Mitochondrial bioenergetic repair + spike clearance |
| Self-initiation | Yes — OTC self-start with physician follow-up | Partly — non-Rx first-line elements are self-startable | Structured 7+ week sequence; physician oversight recommended throughout |
| Monitoring | Spike Ab test every 6–12 months | Symptom-guided; D-dimer, CBC, inflammatory markers | Phase-by-phase tolerance review; watch for Herxheimer-like flares |
| Duration | 3 months minimum; 6–12+ months typical | Individualized; taper on improvement | ~7 weeks to complete all phases; maintenance ongoing |
| Relationship | Complementary and nested: Base Spike Detox compounds appear in I-Recover's first-line tier, and both frameworks are embedded in Phase 3 of the bioenergetic protocol. The three can and should be used together as the foundation of a comprehensive recovery plan. | ||
9. Clinical Safety & Drug Interactions
- Anticoagulants / antiplatelets: nattokinase and bromelain exert potent fibrinolytic effects. Combining them with warfarin, apixaban, rivaroxaban, or dabigatran increases bleeding risk and requires physician supervision.
- Serotonergic medications: methylene blue acts as a monoamine oxidase inhibitor (MAOI) and is strictly contraindicated with SSRIs or SNRIs due to serotonin syndrome risk.
- Anaesthesia / surgery: disclose use of methylene blue, curcumin, nigella sativa, or SSRIs to the anaesthesia team before any procedure.
- Pacing: exercise must stay strictly within Zone 1. Pushing into anaerobic metabolism prematurely can trigger severe post-exertional crashes.
- Soy allergy: avoid nattokinase (fermented soybean origin); bromelain is a reasonable substitute for proteolytic action.
- Pregnancy, breastfeeding, and pediatric use: none of the frameworks above are recommended without direct, individualized physician guidance.
10. Using AI to Personalize Your Protocol
The frameworks above are clinical references — general guidelines based on the best available evidence. Individual response varies enormously: a patient with prominent neurological symptoms and MCAS needs a different emphasis than one whose primary presentation is cardiac or thrombotic. AI assistants can help bridge this gap by cross-referencing your personal medical data against the protocol framework — though they are a preparation tool for physician conversations, not a substitute for one.
| Step | Platform | What to Upload & Ask |
|---|---|---|
| 1 | Gather documents | Spike antibody result; CBC, metabolic panel, CRP, D-dimer; current medication list; symptom journal (score 1–10); vaccination/infection history. |
| 2 | Claude (claude.ai) | Upload lab reports (PDF/image) and ask which elements of the I-Recover or Base Spike Detox protocol are most relevant given your antibody level, medications, and symptoms; ask it to flag interaction risks and suggest monitoring to discuss with your physician. Claude is well suited to nuanced, document-grounded clinical reasoning. |
| 3 | ChatGPT (chat.openai.com) | Upload lab PDFs/images and ask it to cross-reference both protocols against your antibody level, medications, and dominant symptoms, prioritizing what to raise with your doctor. |
| 4 | Gemini (gemini.google.com) | Useful for cross-checking supplement interactions, pulling relevant PubMed abstracts for your specific symptoms, and building a symptom-protocol matrix to bring to your physician. |
| 5 | Perplexity (perplexity.ai) | Strong for rapidly surfacing and citing the latest published literature on a specific supplement-drug interaction or symptom adjunct before your appointment. |
| 6 | Review with your physician | Print or screen-share your AI session summary at your next consultation. Use the IMA/FLCCC provider directory or The Wellness Company telehealth to find a physician familiar with these protocols. |
Sample prompt template (copy, customize, and attach your lab reports as files):
I am seeking help personalizing a spike protein detox and mitochondrial recovery protocol. Background: [vaccinated / unvaccinated / had COVID X times / both]. Spike antibody level: [X U/ml, tested DATE]. Primary symptoms (score 1–10): brain fog, fatigue, chest pain/palpitations, joint pain, tinnitus, shortness of breath, other. Current medications: [list with doses]. Allergies: [soy, NSAIDs, etc.]. Please: (1) identify which phase of the bioenergetic protocol and which tier of I-Recover or Base Spike Detox applies to my profile; (2) flag interactions between my medications and the proposed supplements, especially anticoagulation and serotonergic risk; (3) recommend the most relevant symptom-specific adjuncts; (4) generate a prioritized list of questions for my physician.
Important: AI assistants are not licensed physicians and cannot diagnose or prescribe. Their output is a research aid to help you ask better questions of your healthcare provider — always verify AI-generated suggestions with a qualified physician before changing your treatment.
11. Where to Source the Protocols
The Wellness Company — Ultimate Spike Detox: nattokinase + bromelain + turmeric (curcumin), medicinal-grade dosing researched by Dr. Peter McCullough. Order Ultimate Spike Detox — use code ONEDAYMD for 10% off. Also offers telehealth consultation with physicians familiar with these protocols.
Find a protocol-knowledgeable physician: access ivermectin, LDN, and other Rx components through IMA-affiliated providers. Find a Doctor (IMA Directory) · TWC Virtual Care
Affiliate disclosure: this page contains affiliate links to The Wellness Company (code ONEDAYMD, 10% off). These relationships do not influence editorial content or protocol recommendations.
12. Frequently Asked Questions
What is the McCullough Base Spike Detox?
Nattokinase (2,000 FU / 100 mg BID, empty stomach) + Bromelain (500 mg/day, empty stomach) + Nano/Liposomal Curcumin (500 mg BID, with food). Minimum 3 months; many require 6–12 months or longer. It is the only triple OTC spike-clearance regimen published in the peer-reviewed US medical literature (Cureus, 2023).
What is the FLCCC I-Recover Protocol?
A graduated, symptom-guided protocol from the Independent Medical Alliance (formerly FLCCC) covering three tiers: first-line (intermittent fasting, ivermectin, nattokinase, LDN, melatonin, MCAS management), second-line (Vitamin D3/K2, NAC, omega-3, magnesium, IV Vitamin C), and third-line (HBOT, mitochondrial optimizers, low-dose steroids). Treatment is individualized to the patient's dominant syndrome.
Why sequence these into four phases instead of starting everything at once?
Stimulating metabolism before mitochondria are stabilized can escalate mtROS production, and degrading spike protein too quickly can trigger Herxheimer-like flares or post-exertional crashes. The phased protocol neutralizes oxidative stress first, then recharges NAD+ pools, then clears spike and activates mitophagy, and only then expands aerobic capacity.
How do I use AI to personalize the protocol?
Attach your medical reports — spike antibody result, blood work, medication list, and symptom scores — to Claude, ChatGPT, Gemini, or Perplexity using the sample prompt in Section 10. The AI can help identify which phase and tier apply to your profile, flag drug interactions, recommend symptom-specific adjuncts, and generate physician questions. Always verify AI output with a licensed clinician.
Can I take the Base Spike Detox if I am on blood thinners (warfarin, Eliquis, Xarelto)?
Only under close physician supervision. Both nattokinase (fibrinolytic) and bromelain (prolongs prothrombin time) significantly amplify anticoagulant effects. Dose adjustment of either the supplement or the anticoagulant may be required, with monitoring for bruising and mucosal bleeding.
What spike protein antibody test should I use to monitor progress?
The SARS-CoV-2 Spike Protein Antibody Semi-Quantitative test through Labcorp is the primary recommended test in most US states; Healthlabs.com and Attomarker are alternatives. Establish a baseline before starting any protocol and retest at 6–12 months, not sooner.
Does this apply to Long COVID from infection, not just vaccination?
Yes. All three frameworks were designed for persistent spike protein regardless of whether it originated from infection, vaccination, or both, given the significant pathophysiological overlap between Long COVID and post-vaccine syndrome.
How long does recovery take?
Minimum 3 months for the Base Spike Detox; typically 6–12 months; some patients require over a year. The bioenergetic protocol's four phases run roughly seven weeks before moving into an ongoing maintenance stage, and I-Recover agents are tapered one at a time once improvement is achieved.
References
- Hulscher N, Procter BC, Wynn C, McCullough PA. Clinical Approach to Post-acute Sequelae After COVID-19 Infection and Vaccination. Cureus. 2023;15(11):e49204. PMC10663976
- Halma MTJ, Plothe C, Marik P, Lawrie TA. Strategies for the Management of Spike Protein-Related Pathology. Microorganisms. 2023;11(5):1308. PMID 37317282
- Lee E, Ozigbo AA, Varon J, Halma M, Laezzo M, Ang SP, Iglesias J. Mitochondrial Reactive Oxygen Species: A Unifying Mechanism in Long COVID and Spike Protein-Associated Injury. Biomolecules. 2025;15(9):1339. PMID 41008646
- Charles AL, Debrut L, Oulehri W, et al. Impaired Peripheral Blood Mononuclear Cell (PBMC) Mitochondrial Respiration Is Associated with Mortality and Long COVID Syndrome Severity. Int J Mol Sci. 2025;26(21):10377. PMID 41226417
- Omdal R, Lenning OB, Jonsson G, et al. Long-COVID: assessment of circulating markers suggests no cerebral neuronal damage, neuroinflammation or systemic inflammation. Sci Rep. 2026;16(1):11856. PMID 41775811
- Halma M, Vottero P, Thorp J, Peers T, Tuszynski J, Marik P. The Possible Mechanistic Basis of Individual Susceptibility to Spike Protein Injury. Adv Virol. 2025;2025:7990876. PMID 40599824
- Golstein MA. Post-COVID-19 Vaccine Hyperproduction of Anti-Spike Antibodies and Rheumatological Manifestations. Vaccines (Basel). 2025;13(10):1028. PMID 41150416
- Marik P, Kory P, et al. I-RECOVER Post-Vaccine Treatment Protocol. FLCCC / Independent Medical Alliance. 2022–2024. Download PDF
- Tanikawa T, et al. Degradative Effect of Nattokinase on Spike Protein of SARS-CoV-2. Molecules. 2022;27(17):5405. PMID 36080170
- Stone et al. 62% Normalisation in SpO2 within 24h for severe COVID-19 patients after ivermectin-based combination treatment. COVID. 2022;2(3). MDPI
- Boschi C, et al. SARS-CoV-2 Spike protein and haemagglutination. Int J Mol Sci. 2022;23(24):15480. MDPI
- COVID-OUT Trial. Outpatient treatment of COVID-19 and incidence of long COVID. NEJM Evidence. 2023.
- Lau RI, et al. Gut microbiota in Long COVID. Lancet Infect Dis. 2023. Lancet
- Nicotinamide Riboside RCT for Long COVID cognition. Lancet eClinicalMedicine. Nov 2025. Lancet
- Autopsy Proven Fatal COVID-19 Vaccine-Induced Myocarditis. ESC Heart Failure. 2023.
- Long-term neurological and cognitive impact of COVID-19: systematic review in over 4 million patients. BMC Neurology. 2025.
- Kurosawa Y, et al. Nattokinase pharmacokinetics — D-dimer and FDP elevation after oral single dose. PubMed indexed.
Full Medical Disclaimer: This article is solely for educational purposes regarding potentially beneficial therapies and is not a substitute for professional medical advice, diagnosis, or treatment. Treatment decisions for an individual patient should rely on the judgment of a physician or other qualified health provider. Please also review the FLCCC/IMA full disclaimer at imahealth.org/disclaimers. The AI personalization guidance in Section 10 is intended to help patients prepare for conversations with their physicians and is not a substitute for clinical evaluation.
© 2026 Immune Systems Advisor / OneDayMD Network · Merged & last updated July 30, 2026 · Spike Protein series · FLCCC series · Mitochondrial Health series.
Comments
Post a Comment